All In Biotech

Drug Trial Radar · NCT06131372

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 626 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

626

Actual

Start

Apr 1, 2024

Primary completion

Sep 24, 2025

Study completion Nov 6, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema, semaglutide, cagrilintide or placebo. Which treatment participant will get is decided by chance (like flipping a coin). Study doctor will not know which of the study medicines participant will get. For each participant, the study will last for about 35 weeks.

Conditions

  • Chronic Kidney Disease
  • Type 2 Diabetes
  • Obesity

Interventions

  • CagrilintideDrug

    Participants will receive Cagrilintide subcutaneously.

  • SemaglutideDrug

    Participants will receive semaglutide subcutaneously.

  • PlaceboDrug

    Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in urinary albumin-to-creatinine ratio (UACR)Time frame: From baseline (week 0) to end of treatment (week 26)

Locations

129 sites in 13 countries. Site status is shown where the registry gives one.

  • John Muir Physicians Network

    Concord, California

  • Valley Research

    Fresno, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • North America Research Institute

    San Dimas, California

  • NorCal Endocrinology and Internal Medicine

    San Ramon, California

  • Northeast Research Institute

    Fleming Island, Florida

  • Life Spring Research Foundation LLC

    Miami, Florida

  • Advent Health Translational Research Institute

    Orlando, Florida

  • Velocity Clin. Res Valparaiso

    Valparaiso, Indiana

  • Elite Research Center

    Flint, Michigan

  • Univ. of Nebraska Medical Center_Omaha

    Omaha, Nebraska

  • Albany Medical College

    Albany, New York

  • NYU Langone Nephrology Associates

    Mineola, New York

  • New York University Grossman School of Medicine

    New York, New York

  • Southgate Medical Group, LLP

    West Seneca, New York

  • Carteret Medical Group

    Morehead City, North Carolina

  • Eastern Nephrology Associates, PLLC

    New Bern, North Carolina

  • Brookview Hills Research Associates, LLC

    Winston-Salem, North Carolina

  • Ohio- Advanced Medical Research

    Maumee, Ohio

  • Heritage Valley Multispeciality Group Inc

    Beaver, Pennsylvania

  • Main Street Physician's Care

    Little River, South Carolina

  • Osvaldo A. Brusco MD

    Corpus Christi, Texas

  • Southwest Houston Research Ltd

    Houston, Texas

  • Clinical Advancement Center

    San Antonio, Texas

  • Clinical Investigation Specialists Inc, Kenosha

    Kenosha, Wisconsin

  • Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli

    Buenos Aires, Argentina

  • Centro Médico Privado San Vicente Diabetes

    Córdoba, Argentina

  • Mautalen Salud e investigación

    CABA, Buenos Aires, Argentina

  • Centro de Investigaciones Médicas Mar del Plata

    Mar del Plata, Buenos Aires, Argentina

  • Fundación CESIM

    Santa Rosa, La Pampa Province, Argentina

  • Hospital do Rim e Hipertensao Fundacao Oswaldo Ramos

    São Paulo, Brazil

  • Instituto Pró-Renal Brasil

    Curitiba, Paraná, Brazil

  • Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.

    Porto Alegre, Rio Grande do Sul, Brazil

  • CPCLIN - Centro de Pesquisas Clínicas

    São Paulo, São Paulo, Brazil

  • Centricity Research Calgary Endocrinology

    Calgary, Alberta, Canada

  • Centricity Research Brampton Endocrinology

    Brampton, Ontario, Canada

  • Centricity Research Vaughn Endocrinology

    Concord, Ontario, Canada

  • Centricity Research Etobicoke Endocrinology

    Etobicoke, Ontario, Canada

  • Hamilton Medical Research Group

    Hamilton, Ontario, Canada

  • Bluewater Clin Res Group Inc

    Sarnia, Ontario, Canada

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.